More tools:Markets·Screener·Research·Chat

Generate Biomedicines, Inc. Common Stock (GENB) Financial Statements

Generate Biomedicines, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00X9D0P03
XNAS · usd
15.52▼ 0.38 (-2.39%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)—
EBITDA—
Diluted EPS (TTM)—
EBITDA Margin—
Net Debt—
Trading Information
Previous Close15.90
Day's Range15.20 – 16.23
52-Week Range11.00 – 22.67
Volume976.6K
Avg Volume1.1M
Share Statistics
Shares Outstanding
Employees—
ExchangeXNAS
Listed2026-02-27
Share count as of July 29, 2026
Loading Income Statement…
Key questions about Generate Biomedicines, Inc. Common Stock (GENB)
What is Generate Biomedicines, Inc. Common Stock's Market Cap?
Generate Biomedicines, Inc. Common Stock's Market Cap is $2.0B, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue1234.2%987.5%
Loss from operations
% of revenue-1134.2%-887.5%
Other income (expense), net
Change in fair value of convertible preferred stock warrant liability
Interest expense
Interest income
Foreign currency exchange loss
Total other income (expense), net
Loss before provision for income taxes
Provision for income taxes
Net loss
% of revenue-1065.2%-854.3%
Net loss attributable to non-controlling interests
Net loss attributable to Generate Biomedicines, Inc. stockholders
% of revenue-1065.2%-850.6%
Net loss attributable to Generate Biomedicines, Inc. common stockholders
Net loss per share, basic
Net loss per share, diluted